Antipsychotic Medication Selection and Management

Introduction to Antipsychotic Classification

The American Academy of Pediatrics recommends that first-generation antipsychotics function primarily as CNS dopamine D2 receptor antagonists and are subdivided by potency 2
The traditional classification of antipsychotics into first, second, and third generations is clinically misleading and should not guide treatment selection—instead, choose medications based on their specific receptor profiles, side effect profiles, and patient-specific factors, as suggested by Praxis Medical Insights 1

High-potency first-generation antipsychotics, such as haloperidol and droperidol, are less sedating but significantly more likely to cause extrapyramidal symptoms (EPS) 2, 1
Low-potency first-generation antipsychotics, such as chlorpromazine and thioridazine, are more sedating with fewer extrapyramidal symptoms and have greater anticholinergic, antihistaminic, and alpha-adrenergic receptor activity 2, 4, 1

Second-generation antipsychotics act as serotonin-dopamine receptor antagonists with varying receptor affinities, and examples include amisulpride, olanzapine, risperidone, quetiapine, and clozapine 2, 3
The American Academy of Pediatrics notes that second-generation antipsychotics generally cause more metabolic problems, especially clozapine and olanzapine 2

Third-generation antipsychotics, such as aripiprazole, are distinguished by partial dopamine receptor agonist activity and have a superior metabolic profile with low risk of weight gain and minimal prolactin elevation 2, 1, 3
Aripiprazole is recommended as a first-line choice due to its better metabolic side effect profile, as suggested by Praxis Medical Insights 3

Treatment decisions should be based on individual drug pharmacodynamic profiles, specific side effect profiles, and patient-specific factors rather than generational labels, as recommended by Praxis Medical Insights 1, 3
The selection algorithm suggests starting with aripiprazole as first-line monotherapy, avoiding agents with high anticholinergic properties, and considering specific side effect vulnerabilities 3
Before initiating any antipsychotic, measure BMI, waist circumference, blood pressure, HbA1c, glucose, lipids, prolactin, liver function, urea, electrolytes, complete blood count, and EKG, and follow-up monitoring should include glucose at 4 weeks, BMI/waist/blood pressure weekly for 6 weeks, then all parameters at 3 months and annually 3
The British Journal of Psychiatry recommends that in developing countries where second-generation agents are unavailable, first-generation antipsychotics should be used judiciously at very low doses 5
Praxis Medical Insights suggests avoiding combining multiple QT-prolonging antipsychotics due to fatal arrhythmia risk 4